BR112013016950B8 - Composição para uso no tratamento ou prevenção de um distúrbio relacionado a uma inflamação e/ou alergia - Google Patents
Composição para uso no tratamento ou prevenção de um distúrbio relacionado a uma inflamação e/ou alergiaInfo
- Publication number
- BR112013016950B8 BR112013016950B8 BR112013016950A BR112013016950A BR112013016950B8 BR 112013016950 B8 BR112013016950 B8 BR 112013016950B8 BR 112013016950 A BR112013016950 A BR 112013016950A BR 112013016950 A BR112013016950 A BR 112013016950A BR 112013016950 B8 BR112013016950 B8 BR 112013016950B8
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- inflammation
- composition
- allergy
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/15—Suppositories
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11173000.8A EP2543357B1 (en) | 2011-07-07 | 2011-07-07 | Composition for use in treating and preventing inflammation related disorder |
| US11173000.8 | 2011-07-07 | ||
| PCT/US2012/045238 WO2013006548A2 (en) | 2011-07-07 | 2012-07-02 | Composition for use in treating and preventing inflammation related disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112013016950A2 BR112013016950A2 (pt) | 2020-04-28 |
| BR112013016950B1 BR112013016950B1 (pt) | 2023-04-11 |
| BR112013016950B8 true BR112013016950B8 (pt) | 2023-10-10 |
Family
ID=44512628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013016950A BR112013016950B8 (pt) | 2011-07-07 | 2012-07-02 | Composição para uso no tratamento ou prevenção de um distúrbio relacionado a uma inflamação e/ou alergia |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9370575B2 (enExample) |
| EP (1) | EP2543357B1 (enExample) |
| JP (1) | JP6100171B2 (enExample) |
| KR (1) | KR20130121893A (enExample) |
| CN (2) | CN107551273A (enExample) |
| AU (1) | AU2012279133B2 (enExample) |
| BR (1) | BR112013016950B8 (enExample) |
| CA (1) | CA2820977C (enExample) |
| DK (1) | DK2543357T3 (enExample) |
| EA (1) | EA029905B1 (enExample) |
| ES (1) | ES2667854T3 (enExample) |
| HU (1) | HUE037474T2 (enExample) |
| LT (1) | LT2543357T (enExample) |
| NO (1) | NO2543357T3 (enExample) |
| PL (1) | PL2543357T3 (enExample) |
| PT (1) | PT2543357T (enExample) |
| TW (1) | TWI533874B (enExample) |
| WO (1) | WO2013006548A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2543357T3 (enExample) * | 2011-07-07 | 2018-08-18 | ||
| ES2665254T3 (es) | 2011-07-12 | 2018-04-25 | Holy Stone Healthcare Co., Ltd. | Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas |
| KR101412776B1 (ko) | 2013-03-11 | 2014-07-01 | 가톨릭대학교 산학협력단 | 각결막염 치료용 점안제 조성물 및 이의 제조 방법 |
| US9539265B2 (en) | 2013-03-15 | 2017-01-10 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
| WO2014142938A1 (en) * | 2013-03-15 | 2014-09-18 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
| JPWO2015076294A1 (ja) * | 2013-11-22 | 2017-03-16 | キユーピー株式会社 | 薬剤の副作用である胃潰瘍の発症抑制方法、および胃潰瘍発症が抑制された経口薬剤組成物ならびにその製造方法 |
| CN103655601B (zh) * | 2013-12-31 | 2019-10-25 | 上海建华精细生物制品有限公司 | 一种用于膀胱灌洗的组合物 |
| EP2985019B1 (en) | 2014-08-16 | 2021-10-20 | Church & Dwight Co., Inc. | Nasal composition having anti-viral properties |
| EP2985027B1 (en) * | 2014-08-16 | 2021-03-31 | Church & Dwight Co., Inc. | Nasal composition comprising mixture of hyaluronic acids and saline solution |
| WO2019202017A1 (en) | 2018-04-18 | 2019-10-24 | i.com medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
| EP3781116A1 (en) * | 2018-04-18 | 2021-02-24 | i.com Medical GmbH | High molecular weight hyaluronic acid for enhancing epithelial survival and reconstitution of body surfaces |
| IT201800007683A1 (it) * | 2018-07-31 | 2020-01-31 | Altergon Sa | Composizioni cooperative sinergiche utili per aumento del tessuto molle, rilascio di farmaco e campi correlati |
| US12268706B2 (en) | 2019-01-31 | 2025-04-08 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
| CN109924485A (zh) * | 2019-03-29 | 2019-06-25 | 华熙生物科技股份有限公司 | 一种含透明质酸的减肥保健食品及其制备方法 |
| US20210000910A1 (en) | 2019-07-03 | 2021-01-07 | Jysk Skin Solutions Pte Ltd | Topical compositions |
| CN110698925B (zh) * | 2019-10-16 | 2022-03-08 | 江苏科技大学 | 一种纳米印刷导电油墨组合物及其制备方法和应用 |
| US11801127B2 (en) | 2020-04-07 | 2023-10-31 | Maurice Matthew Trentel | Method and system for a modular dental device |
| IT202100021992A1 (it) * | 2021-08-27 | 2023-02-27 | Neilos S R L | Composizione per la prevenzione e/o il trattamento delle patologie gastriche ed esofagee |
| CN116059241B (zh) * | 2021-11-04 | 2024-12-31 | 华熙生物科技股份有限公司 | 提高机体免疫力、促进胃肠道健康的含透明质酸或其盐的组合物及其应用 |
| US12083204B2 (en) | 2022-06-02 | 2024-09-10 | L'oreal | Topical composition for homeostatic delivery of nitric oxide and uses thereof |
| CN116473994A (zh) * | 2023-04-19 | 2023-07-25 | 江苏省中医药研究院 | 透明质酸及其金属盐在制备治疗便秘型肠易激综合征药物中的应用 |
| WO2025122826A1 (en) * | 2023-12-07 | 2025-06-12 | University Of Montana | Hyaluronic acid-nonsteroidal anti-inflammatory drug conjugates for treating inflammation-mediated pathologies |
| IL311338A (en) * | 2024-03-07 | 2025-10-01 | Ariel Scient Innovations Ltd | Using hyaluronic acid to treat mental disorders |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1229075B (it) | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
| AU600483B2 (en) | 1986-03-14 | 1990-08-16 | Bio-Technology General Corporation | Heavy metal salts of hyaluronic acid |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| JP2945993B2 (ja) | 1989-12-05 | 1999-09-06 | 武田薬品工業株式会社 | 外用剤 |
| US5095037B1 (en) * | 1989-12-21 | 1995-12-19 | Nissho Kk | Combined anti-inflammatory agent |
| US5492936A (en) * | 1990-11-30 | 1996-02-20 | Allergan, Inc. | Bimodal molecular weight hyaluronate formulations and methods for using same |
| RU2119794C1 (ru) * | 1992-06-30 | 1998-10-10 | Проктер энд Гэмбл Фармасьютикалз, Инк. | Использование фосфонатов и нестероидных противовоспалительных лекарственных средств для лечения артрита, способ лечения |
| CA2154103C (en) | 1995-07-18 | 1998-02-24 | Samuel Simon Asculai | Treatment of mucous membrane disease, trauma or condition and for the relief of pain |
| JPH10226641A (ja) * | 1997-02-14 | 1998-08-25 | Kureha Chem Ind Co Ltd | 関節症治療製剤 |
| US6551632B2 (en) * | 1997-04-01 | 2003-04-22 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
| CA2208924A1 (en) * | 1997-07-09 | 1999-01-09 | Hyal Pharmaceutical Corporation | Sparing paclitaxel by the use of hyaluronan |
| CA2441007C (en) * | 2001-03-15 | 2009-06-09 | Enteron Pharmaceuticals, Inc. | Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids |
| US6825166B2 (en) * | 2001-03-23 | 2004-11-30 | Tapestry Pharmaceuticals, Inc. | Molecular conjugates for use in treatment of cancer |
| DE60231295D1 (de) * | 2001-04-04 | 2009-04-09 | Ortho Mcneil Janssen Pharm | R und ppar modulatoren |
| US20030008844A1 (en) * | 2001-05-17 | 2003-01-09 | Keryx Biopharmaceuticals, Inc. | Use of sulodexide for the treatment of inflammatory bowel disease |
| US20030171332A1 (en) | 2001-05-23 | 2003-09-11 | Abraham William M. | Treatment of respiratory conditions associated with bronchoconstriction with aerosolized hyaluronic acid |
| JP4335005B2 (ja) | 2001-10-18 | 2009-09-30 | 生化学工業株式会社 | 炎症性腸疾患処置剤 |
| US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
| DE20318634U1 (de) | 2003-11-13 | 2004-02-26 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden |
| NZ549010A (en) * | 2004-01-07 | 2010-07-30 | Seikagaku Kogyo Co Ltd | Hyaluronic acid derivative and drug containing the same |
| CA2553775A1 (en) * | 2004-01-20 | 2005-08-11 | Richard F. Harty | Compositions and methods of treatment for inflammatory diseases |
| MY162179A (en) * | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| US7879818B2 (en) | 2005-12-23 | 2011-02-01 | Janos Borbely | Hyaluronic acid-based cross-linked nanoparticles |
| EP2026821B1 (en) * | 2006-05-11 | 2009-08-26 | Sandra Gobbo | Hyaluronic acid binary mixtures and therapeutic use thereof |
| AU2007275660B2 (en) | 2006-07-19 | 2012-08-02 | The Board Of Regents Of The University Of Texas System | Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease |
| FR2919185B1 (fr) * | 2007-07-23 | 2010-09-10 | Ard Sa | Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de l'etat des muqueuses |
| US8394782B2 (en) * | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
| TWI516269B (zh) * | 2009-08-14 | 2016-01-11 | 禾伸堂生技股份有限公司 | 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物 |
| TWI383796B (zh) * | 2009-08-14 | 2013-02-01 | Holy Stone Healthcare Co Ltd | Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer |
| US8575130B2 (en) | 2010-01-04 | 2013-11-05 | Holy Stone Healthcare Co., Ltd. | Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease |
| NO2543357T3 (enExample) * | 2011-07-07 | 2018-08-18 |
-
2011
- 2011-07-07 NO NO11173000A patent/NO2543357T3/no unknown
- 2011-07-07 PL PL11173000T patent/PL2543357T3/pl unknown
- 2011-07-07 EP EP11173000.8A patent/EP2543357B1/en active Active
- 2011-07-07 PT PT111730008T patent/PT2543357T/pt unknown
- 2011-07-07 ES ES11173000.8T patent/ES2667854T3/es active Active
- 2011-07-07 LT LTEP11173000.8T patent/LT2543357T/lt unknown
- 2011-07-07 DK DK11173000.8T patent/DK2543357T3/en active
- 2011-07-07 HU HUE11173000A patent/HUE037474T2/hu unknown
-
2012
- 2012-06-27 TW TW101122966A patent/TWI533874B/zh active
- 2012-07-02 WO PCT/US2012/045238 patent/WO2013006548A2/en not_active Ceased
- 2012-07-02 CN CN201710722519.4A patent/CN107551273A/zh active Pending
- 2012-07-02 AU AU2012279133A patent/AU2012279133B2/en active Active
- 2012-07-02 US US13/992,772 patent/US9370575B2/en active Active
- 2012-07-02 CN CN2012800041922A patent/CN103260629A/zh active Pending
- 2012-07-02 KR KR1020137016687A patent/KR20130121893A/ko not_active Ceased
- 2012-07-02 JP JP2013549623A patent/JP6100171B2/ja active Active
- 2012-07-02 EA EA201300608A patent/EA029905B1/ru unknown
- 2012-07-02 CA CA2820977A patent/CA2820977C/en active Active
- 2012-07-02 BR BR112013016950A patent/BR112013016950B8/pt active IP Right Grant
-
2018
- 2018-04-09 US US15/948,504 patent/US10471151B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2820977C (en) | 2016-01-19 |
| EA029905B1 (ru) | 2018-05-31 |
| TWI533874B (zh) | 2016-05-21 |
| HUE037474T2 (hu) | 2018-08-28 |
| US9370575B2 (en) | 2016-06-21 |
| AU2012279133A1 (en) | 2013-07-04 |
| KR20130121893A (ko) | 2013-11-06 |
| WO2013006548A2 (en) | 2013-01-10 |
| CA2820977A1 (en) | 2013-01-10 |
| EP2543357B1 (en) | 2018-03-21 |
| US20180221492A1 (en) | 2018-08-09 |
| CN107551273A (zh) | 2018-01-09 |
| LT2543357T (lt) | 2018-06-11 |
| AU2012279133B2 (en) | 2015-08-20 |
| NZ611857A (en) | 2015-09-25 |
| WO2013006548A3 (en) | 2013-04-11 |
| PL2543357T3 (pl) | 2018-08-31 |
| US10471151B2 (en) | 2019-11-12 |
| DK2543357T3 (en) | 2018-07-02 |
| BR112013016950A2 (pt) | 2020-04-28 |
| EP2543357A1 (en) | 2013-01-09 |
| EA201300608A1 (ru) | 2014-05-30 |
| JP2014502642A (ja) | 2014-02-03 |
| NO2543357T3 (enExample) | 2018-08-18 |
| CN103260629A (zh) | 2013-08-21 |
| TW201302190A (zh) | 2013-01-16 |
| JP6100171B2 (ja) | 2017-03-22 |
| PT2543357T (pt) | 2018-04-30 |
| BR112013016950B1 (pt) | 2023-04-11 |
| ES2667854T3 (es) | 2018-05-14 |
| US20140141077A1 (en) | 2014-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013016950B8 (pt) | Composição para uso no tratamento ou prevenção de um distúrbio relacionado a uma inflamação e/ou alergia | |
| BR112015005048A8 (pt) | métodos para tratar dermatite atópica por administração de antagonista il-4r | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| BR112014032699A2 (pt) | métodos de tratamento de síndrome metabólica pediátrica | |
| MX365781B (es) | Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas. | |
| BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| WO2013009519A3 (en) | Materials for treating and preventing mucosa related disease | |
| BR112015009913A2 (pt) | composições farmacêuticas para o tratamento de doenças mediadas por cftr | |
| EA201071320A1 (ru) | Активаторы глюкокиназы | |
| BR112015023520A2 (pt) | purificação do conjugado de anticorpo-fármaco (adc) | |
| BR112019011702A2 (pt) | tratamento de uma doença do trato gastrointestinal com um inibidor de il-12/il-23 liberado usando um dispositivo ingerível | |
| HK1245100A1 (zh) | 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法 | |
| BR112014029442A2 (pt) | composições antimucosas à base de xilitol e métodos e composições relacionados | |
| UA111199C2 (uk) | Співкристали l-проліну і лимонної кислоти з (2s,3r,4r,5s,6r)-2-(3-((5-(4-фторфеніл)тіофен-2-іл)метил)-4-метилфеніл)-6-(гідроксиметил)тетрагідро-2h-піран-3,4,5-тріолом | |
| EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
| WO2007111992A3 (en) | Methods and compositions for treating hypercholesterolemia and atherosclerosis | |
| MX340985B (es) | Compuestos de n-heteroarilo. | |
| HK1208154A1 (en) | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | |
| DOP2011000091A (es) | Particulas inhalables que comprenden tiotropio | |
| BR112013031652A2 (pt) | métodos de tratamento para doenças retinais | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| BR112014032627A8 (pt) | Pró-fármacos de rebamipida, método para produzir o mesmo, e uso do mesmo | |
| CY1121238T1 (el) | Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων | |
| EA201001162A1 (ru) | Способы лечения расстройств с уменьшением костной массы с использованием антагониста gm-csf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE EP 11173000.8 DE 07/07/2011 REIVINDICADA NO PCT/US2012/045238, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT (?AIHOL CORPORATION?) SER DISTINTO DAQUELES QUE DEPOSITARAM A PRIORIDADE REIVINDICADA E NAO FOI APRESENTADO O DOCUMENTO COMPROBATORIO DE CESSAO NO PRAZO LEGAL, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 2 DA RESOLUCAO INPIPR 179/2017. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B12F | Other appeals [chapter 12.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/07/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2727 DE 11/04/2023, QUANTO AO ITEM (30) PRIORIDADE UNIONISTA. |